Rocket Pharmaceuticals, Inc. Derivative, Gain (Loss) on Derivative, Net
Rocket Pharmaceuticals, Inc. (RCKT) reported Derivative, Gain (Loss) on Derivative, Net of -$42.79 million for the 12-month period ending 2015-12-31, per its 10-K filed 2017-03-16.
Discontinued › Income Statement › Other Income
us-gaap:DerivativeGainLossOnDerivativeNet · last filed 2017-03-16
- Rocket Pharmaceuticals, Inc. derivative, gain (loss) on derivative, net for the quarter ending 2015-12-31 was $0.00.
- Rocket Pharmaceuticals, Inc. derivative, gain (loss) on derivative, net for the quarter ending 2015-09-30 was -$46.65M.
- Rocket Pharmaceuticals, Inc. derivative, gain (loss) on derivative, net for the quarter ending 2015-06-30 was $1.86M.
- Rocket Pharmaceuticals, Inc. derivative, gain (loss) on derivative, net for the quarter ending 2015-03-31 was $2.00M.
- Rocket Pharmaceuticals, Inc. derivative, gain (loss) on derivative, net for fiscal 2015 was -$42.79M.
| Period end | Derivative, Gain (Loss) on Derivative, Net 3 month | Derivative, Gain (Loss) on Derivative, Net 6 month | Derivative, Gain (Loss) on Derivative, Net 9 month | Derivative, Gain (Loss) on Derivative, Net 12 month |
|---|---|---|---|---|
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$46.65M derived: sum of 2 quarters · filed 2017-03-16 | -$44.79M derived: sum of 3 quarters · filed 2017-03-16 | -$42.79M 10-K · filed 2017-03-16 |
| 2015-09-30 | -$46.65M 10-Q · filed 2016-11-09 | -$44.79M derived: sum of 2 quarters · filed 2016-11-09 | -$42.79M 10-Q · filed 2016-11-09 | |
| 2015-06-30 | $1.86M 10-Q · filed 2016-08-10 | $3.86M 10-Q · filed 2016-08-10 | ||
| 2015-03-31 | $2.00M 10-Q · filed 2016-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |